KLRS FY 2022 Earnings — Kalaris Therapeutics Inc Revenue & Financial Results | Market Cap Arena

KLRSKalaris Therapeutics Inc

$187M

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$14M

Net Income

-$15M

EPS (Diluted)

$-50.62

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$271,000

Balance Sheet

Total Assets

$4M

Total Liabilities

$34M

Stockholders' Equity

-$30M

Cash & Equivalents

$3M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$1M	+100.0%
Operating Income	-$14M	-$170M	+91.8%
Net Income	-$15M	-$172M	+91.0%